Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Miracor's cardiac perfusion technology enters first human trial

This article was originally published in Clinica

Executive Summary

Miracor Medical Systems has begun the first human trial of the PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) system. The system is designed to improve blood flow to the heart muscle following percutaneous coronary intervention (PCI) to help repair cardiac tissue in patients with acute coronary syndrome (ACS).

Advertisement

Related Content

Market Intel: Heart Attack Therapy Firms Seek Unobstructed Path For MVO Solutions

Topics

Advertisement
UsernamePublicRestriction

Register

MT096032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel